Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice

Hiromi Okamoto,Masataka Oitate,Katsunobu Hagihara,Hideyuki Shiozawa,Yoshitake Furuta,Yusuke Ogitani,Hiroshi Kuga

DOI: https://doi.org/10.1080/00498254.2020.1755909

2020-04-22

Xenobiotica

Abstract:Trastuzumab deruxtecan (T-DXd, DS-8201a) is an antibody-drug conjugate (ADC), comprising an anti-HER2 antibody (Ab) at a drug-to-Ab ratio of 7–8 with the topoisomerase I inhibitor DXd. In this study, we investigated the pharmacokinetics (PK), biodistribution, catabolism, and excretion profiles of T-DXd in HER2-positive tumour-bearing mice.Following intravenous (iv) administration of T-DXd, the PK profiles of T-DXd and total Ab (the sum of conjugated and unconjugated Ab) were almost similar, indicating that the linker is stable during circulation. Biodistribution studies using radiolabelled T-DXd demonstrated tumour-specific distribution and long-term retention. DXd was the main catabolite released from T-DXd in tumours, with exposure levels at least five times higher than those in normal tissues and seven times higher than those achieved by non-targeted control ADC. Following iv administration of DXd, it was rapidly cleared from the circulation (T1/2; 1.35 h) and excreted mainly through faeces as its intact form.The PK profiles reveal that T-DXd effectively delivers the expected payload, DXd, to tumours, while minimising payload exposure to the systemic circulation and normal tissues. The released DXd is rapidly cleared from systemic circulation, presumably via the bile with negligible metabolism, and excreted through the faeces.

pharmacology & pharmacy,toxicology

What problem does this paper attempt to address?

### Problems the paper attempts to solve

This paper aims to explore the pharmacokinetic (PK), biodistribution, metabolism and excretion characteristics of a new anti - HER2 antibody - drug conjugate (ADC), Trastuzumab Deruxtecan (T - DXd, DS - 8201a), in HER2 - positive tumor - bearing mice. Specifically, the main research problems include:

1. **Evaluating the pharmacokinetic characteristics of T - DXd**:
- Studying the clearance rate, half - life and distribution volume of T - DXd and its total antibody (conjugated and unconjugated Ab) in vivo.
- Verifying the stability of the linker of T - DXd in the systemic circulation.

2. **Analyzing the biodistribution of T - DXd**:
- Using radiolabeled T - DXd ([3H]T - DXd and [14C]T - DXd) to study its distribution in different tissues, especially the specific distribution and long - term retention in tumor tissues.

3. **Exploring the metabolism and excretion pathways of T - DXd**:
- Analyzing the metabolites of DXd (the payload released by T - DXd) in vivo and their excretion pathways, especially the excretion through bile and feces.

4. **Comparing the effects of T - DXd and non - targeted control ADC**:
- Comparing the DXd exposure in tumors and other normal tissues between T - DXd and non - targeted control ADC to evaluate the selectivity and safety of T - DXd.

5. **Explaining the pharmacological effects and safety mechanisms of T - DXd**:
- Explaining the favorable safety characteristics of T - DXd in pre - clinical and clinical studies from a pharmacokinetic perspective, especially in cancer patients.

### Key findings

1. **Pharmacokinetic stability**:
- The PK curves of T - DXd and the total antibody are similar, indicating that the linker is stable in the systemic circulation and no significant degradation occurs.

2. **Specific tumor distribution**:
- The radiolabeled T - DXd has the highest radioactivity in tumor tissues and can still be detected two weeks later, while the radioactivity in other tissues is significantly reduced.

3. **Efficient release of DXd**:
- In tumor tissues, DXd is the main metabolite, indicating that T - DXd can effectively release the expected payload.

4. **Rapid clearance and excretion**:
- DXd is rapidly cleared in the systemic circulation and is mainly excreted through bile and feces, with almost no metabolism.

These research results are helpful for understanding the pharmacological effects and safety mechanisms of T - DXd in the treatment of HER2 - positive tumors and provide theoretical support for future clinical applications.